Gilead Sciences
GILD
1,701 hedge funds and large institutions have $80.6B invested in Gilead Sciences in 2023 Q2 according to their latest regulatory filings, with 115 funds opening new positions, 643 increasing their positions, 710 reducing their positions, and 134 closing their positions.
35% more call options, than puts
Call options by funds: $929M | Put options by funds: $687M
0.3% more ownership
Funds ownership: 83.46% → 83.76% (+0.3%)
9% less repeat investments, than reductions
Existing positions increased: 643 | Existing positions reduced: 710
2% less funds holding
Funds holding: 1,735 → 1,701 (-34)
6% less capital invested
Capital invested by funds: $86.1B → $80.6B (-$5.5B)
14% less first-time investments, than exits
New positions opened: 115 | Existing positions closed: 134
36% less funds holding in top 10
Funds holding in top 10: 45 → 29 (-16)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$1B |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$353M |
| 3 |
Barclays
London,
United Kingdom
|
+$170M |
| 4 |
VanEck Associates
New York
|
+$146M |
| 5 |
State Street
Boston,
Massachusetts
|
+$121M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$402M |
| 2 |
Envestnet Asset Management
Chicago,
Illinois
|
-$362M |
| 3 |
Renaissance Technologies
New York
|
-$224M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$185M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$164M |
GILD Hedge Fund Activity: Q2 2023 in Review
1,701 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q2 2023, worth a combined $80.6B — down 6.4% from $86.1B a quarter earlier.
Sellers outnumbered buyers: 134 funds closed out of GILD and 115 opened new positions — a net loss of 19 holders — while 710 trimmed existing stakes and 643 added.
The largest buyer was Wellington Management Group, adding an estimated $1B. The largest seller was Marshall Wace, cutting an estimated $402M.
- 1,701 institutional investors held Gilead Sciences (GILD) as of Q2 2023, down from 1,735 in Q1 2023.
- Funds reported $80.6B of Gilead Sciences stock for Q2 2023, down 6.4% quarter-over-quarter.
- 115 funds opened new Gilead Sciences positions in Q2 2023 and 134 closed out, a net change of -19 holders.
- The largest Gilead Sciences buyer in Q2 2023 was Wellington Management Group, an estimated $1B added.
- The largest Gilead Sciences seller in Q2 2023 was Marshall Wace, an estimated $402M sold.
Based on aggregated 13F filings for Q2 2023.